Skip to main content
Top

Supportive Care in Cancer

Issue 3/1999

Content (13 Articles)

SPECIAL ARTICLE

Breaking bad news to patients: physicians' perceptions of the process

J. T. Ptacek, E. A. Fries, T. L. Eberhardt, J. J. Ptacek

ORIGINAL ARTICLE

Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale

M. Costantini, Marco Musso, Paola Viterbori, Francesca Bonci, Lucia Del Mastro, Ornella Garrone, Marco Venturini, Gabriella Morasso

ORIGINAL ARTICLE

The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients

T. Morita, Junichi Tsunoda, Satoshi Inoue, Satoshi Chihara

ORIGINAL ARTICLE

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)

P. J. Hollen, Richard J. Gralla, Mark G. Kris, Shirley W. Eberly, Christopher Cox

ORIGINAL ARTICLE

Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment

V. Minotti, G. Gentile, G. Bucaneve, A. P. Iori, A. Micozzi, F. Cavicchi, G. Barbabietola, G. Landonio, F. Menichetti, P. Martino, A. Del Favero

ORIGINAL ARTICLE

Evaluation of a national breast cancer information service: the Iranian experience

A. Montazeri, Shahpar Haghighat, Mariam Vahdani, Soghra Jarvandi, Iraj Harirchi

SHORT COMMUNICATION

Skin necrosis in the presence of paclitaxel and fluorometholone

A. Aboolian, Robert Tornambe, Marco Ricci, Raymond D. LaRaja

ORIGINAL ARTICLE

Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

M. E. E. Sabbioni, Monica Castiglione, Christoph Hürny, Hans-Peter Siegrist, Marisa Bacchi, Jürg Bernhard, Beat Thürlimann, Hervé Bonnefoi, Lucien Perey, Aron Goldhirsch, Hans-Jörg Senn

LETTER TO THE EDITOR

E. Castagnola, Claudio Viscoli

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine